Substituting whiterice with brown rice for 16 weeks does not substantially affect metabolic risk factors in middle-aged Chinese men and women with diabetes or a high risk for diabetes.
Zhang G, Pan A, Zong G, Yu Z, Wu H, Chen X, Tang L, Feng Y, Zhou H, Chen X, Li H, Hong B, Malik VS, Willett WC, Spiegelman D, Hu FB, Lin X. J Nutr. 2011 Sep;141(9):1685-90. Epub 2011 Jul 27.
Key Laboratory of Nutrition and Metabolism, Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences and Graduate School of the Chinese Academy of Sciences, Shanghai, China.
Epidemiologic studies have suggested that higher consumption of whiterice (WR) is associated with increased risk for type 2 diabetes mellitus.
However, it is unclear whether substituting brown rice (BR) for WR can improve metabolic risk factors. A total of 202 middle-aged adults with diabetes or a high risk for diabetes were randomly assigned to a WR (n = 101) or BR group (n = 101) and consumed the rice ad libitum for 16 wk.
Metabolic risk markers, including BMI, waist circumference, blood pressure, glycated hemoglobin, and serum lipid, glucose, and insulin concentrations were measured before and after the intervention.
Over the course of the intervention, no between-group differences were found for any markers except the serum LDL cholesterol concentration, which decreased more in the WR group compared to the BR group (P = 0.02). However, this effect was observed only among participants with diabetes (n = 47).
The reversion rate of reduced serum HDL cholesterol was marginally higher in the BR group (14.9%) than in the WR group (6.9%) (P = 0.07).
Among participants with diabetes, a greater reduction in diastolic blood pressure was observed in the BR group compared to the WR group (P = 0.02).
Our study suggests that incorporating BR into the daily diet for 16 wk did not substantially improve metabolic risk factors.
Further studies with larger sample sizes, longer durations of follow-up, and different varieties of rice are needed to carefully examine the role of BR in the prevention and management of diabetes.
MJoTA has been published since 2006 by Emerald Pademelon Press LLC. PO Box 381 Haddonfield, NJ 08033, USA. MJoTA.org, MedicalWritingInstitute.org and drsusanna.org host MJoTA, and the Medical Writing Institute, which is a New Jersey nonprofit corporation. All inquiries for the Medical Writing Institute or Emerald Pademelon Press LLC: firstname.lastname@example.org. Contact the publisher directly through WhatsApp, Linkedin, Facebook click here